Specialized Cancer Center Support Grant

专门癌症中心支持补助金

• 批准号: 7934383
• 负责人: DENNIS CARSON
• 金额: $ 9.27万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-07-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7934383
• 关键词: Basic Science; Biological Sciences; Biotechnology; California; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Clinical; Comprehensive Cancer Center; Diagnosis; Direct Costs; Division of Cancer Prevention; Funding; Goals; Hematologic Neoplasms; Institutes; Laboratories; Leadership; Neoplasm Metastasis; New Agents; Patients; Peer Review; Physicians; Prevention; Private Sector; Reporting; Research; Research Institute; Research Personnel; Resource Sharing; Scientist; Site; Source; Symptoms; Testing; Therapeutic Clinical Trial; Translational Research; Translations; Universities; Vision; anticancer research; cancer genetics; cancer health disparity; cancer prevention; cancer site; cancer therapy; design; interdisciplinary collaboration; member; novel therapeutics; prevent; programs; square foot; tumor growth

DESCRIPTION (provided by applicant): The Moores Cancer Center (MCC) at the University of California, San Diego (UCSD) is a matrix cancer center with 225 members from 18 university departments. Peer-reviewed funding for UCSD investigators is $102 million (direct cost), of which $32 million originates from the NCI. An additional $13.8 million from non-peer reviewed sources results in total direct cost funding of $115.8 Million. A new 270,000 sq ft multipurpose Cancer Center building opened in April, 2005. It is located on the UCSD campus, surrounded by several other major life science research institutes and 470 biotechnology companies in La Jolla, which is commonly referred to as the "Golden Triangle" of biotechnology. The MCC is the only NCI designated comprehensive cancer center in this prolific cancer research region. Given this advantage, the long-term vision for the Moores Cancer Center is to become the major hub in Southern California for the discovery and testing of new agents for the prevention, diagnosis and treatment of cancer. The new MCC building was specifically designed to: (1) stimulate interdisciplinary collaboration between physicians and scientists in the Center's Divisions of Cancer Prevention and Control, Basic Science, and Clinical and Translational Research; (2) assemble in a common and accessible site the extensive NCI supported Shared Resources, and (3) act as a central gathering site for cancer translational researchers within the public and private sectors of Southern California. Since the building's opening only one year ago, patient accrual to therapeutic clinical trials has more than doubled. This application reports on 11 Shared Resources and seven Research Programs which reflect the scientific strengths and goals of the MCC. Four programs are existing - Cancer Biology, Cancer Genetics, Cancer Prevention and Control, Cancer Symptom Control, and three are new- Hematologic Malignancies, Reducing Cancer Disparities, and Tumor Growth, Invasion and Metastasis. This application also summarizes our plans for the deployment of new therapeutics originating from research occurring in MCC laboratories and collaborating institutes. The leadership of the MCC, supported by the UCSD administration, places the highest priority on research discovery and its translation into meaningful advances to prevent, ameliorate and eliminate the burden of cancer.

描述（由申请人提供）：加利福尼亚大学圣地亚哥分校（UCSD）的摩尔癌中心（MCC）是一个基质癌症中心，有225名来自18个大学系的成员。 UCSD调查人员对同行评审的资金为1.02亿美元（直接成本），其中3200万美元来自NCI。从非对方审查的来源中另外的1380万美元导致直接成本资金为1.158亿美元。一座新的270,000平方英尺多用途癌症中心大楼于2005年4月开业。它位于UCSD校园，周围是La Jolla的其他几家主要生命科学研究学院和470个生物技术公司，通常称为生物技术的“金三角”。 MCC是这个多产癌症研究区域中唯一指定的NCI综合癌症中心。鉴于这一优势，摩尔癌中心的长期视力是成为南加州的主要枢纽，以发现和测试新药物预防，诊断和治疗癌症。 新的MCC大楼专门设计为：（1）刺激该中心预防和控制，基础科学以及临床和转化研究中心的医生与科学家之间的跨学科合作； （2）在一个共同且可访问的地点组装大量的NCI支持共享资源，（3）作为南加州公共和私营部门癌症转化研究人员的中心聚会场所。自一年前建筑物开业以来，患者到治疗性临床试验的应计值增加了一倍以上。该应用程序报告了11个共享资源和7项研究计划，这些计划反映了MCC的科学优势和目标。存在四个程序 - 癌症生物学，癌症遗传学，预防和控制，癌症症状控制，三个是新血液系统恶性肿瘤，减少癌症差异以及肿瘤生长，侵袭和转移。 该应用程序还总结了我们部署新治疗剂的计划，该疗法源自MCC实验室和合作机构的研究。在UCSD管理局的支持下，MCC的领导层将研究发现的最高优先事项及其转化为有意义的进步，以预防，改善和消除癌症的负担。